How Can I Help You?
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium
In this retrospective study, the Paediatric PSC Consortium compared the health of patients with PSC and IBD who had taken oral vancomycin (OV) to PSC-IBD patients who had not taken OV.
Out of 113 patients with PSC-IBD, 70 were treated with OV, and they had a better chance of their IBD going into remission compared to 210 patients who weren’t treated with OV.
Results show that OV was associated with greater odds of IBD clinical and endoscopic remission—even with those who had more severe IBD at the start. OV treatment was also associated with lower CRP and better blood test results, indicating less inflammation and better overall health.